US2005239840A1PendingUtilityA1
Benzothiophenes, formulations containing same, and methods
Individually held — no corporate assignee on recordPriority: Mar 26, 1996Filed: Mar 30, 2005Published: Oct 27, 2005
Est. expiryMar 26, 2016(expired)· nominal 20-yr term from priority
Inventors:Gordon Nelson ArbuthnotBrian Weston DalderKerry John HartauerWayne Douglas LukeRobert Eugene Stratford, Jr.
A61P 35/00A61P 19/10C07D 333/56
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
Claims
exact text as granted — not AI-modified1 . A compound of formula I
and pharmaceutically acceptable salts and solvates thereof, characterized in that the compound is in particulate form, said particles having a mean particle size of less than about 25 microns.
2 . The compound of claim 1 wherein said particles have a mean particle size of between about 5 and about 20 microns.
3 . The compound of claim 2 wherein at least about 90% of said particles have a size of less than about 50 microns.
4 . The compound of claim 3 wherein at least 90% of said particles have a size of less than about 35 microns.
5 . A compound of claim 1 which is the non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride having substantially the following X-ray diffraction pattern obtained with copper radiation:
d-line spacing
I/I o
(Angstroms)
(×100)
13.3864
71.31
9.3598
33.16
8.4625
2.08
7.3888
7.57
6.9907
5.80
6.6346
51.04
6.1717
29.57
5.9975
5.67
5.9135
9.87
5.6467
38.47
5.4773
10.54
5.2994
4.74
4.8680
4.03
4.7910
5.98
4.6614
57.50
4.5052
5.75
4.3701
9.03
4.2516
69.99
4.2059
57.64
4.1740
65.07
4.0819
12.44
3.9673
22.53
3.9318
100.00
3.8775
9.07
3.7096
33.38
3.6561
21.65
3.5576
3.36
3.5037
7.97
3.4522
18.02
3.4138
4.65
3.2738
10.23
3.1857
8.90
3.1333
6.24
3.0831
9.43
3.0025
12.13
2.9437
4.96
2.8642
7.70
2.7904
11.95
2.7246
3.05
2.6652
3.32
2.5882
7.30
6 . A pharmaceutical formulation comprising or formulated using the compound of claim 5 and one or more pharmaceutically acceptable carriers, diluents, or excipients.
7 . A pharmaceutical composition comprising or formulated using a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.
8 . A method of inhibiting osteoporosis comprising administering an effective amount of a compound of formula I to a person in need thereof.
9 . A method of lowering serum lipid levels comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, to a person in need thereof.
10 . A method for preventing breast cancer comprising administering to a woman in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof.
11 . An article of manufacture comprising packaging material containing a pharmaceutical formulation, said packaging material further containing labelling indicating said pharmaceutical formulation is useful for inhibiting a human pathology, said pharmaceutical formulation comprising or formulated using a compound of claim 1 .
12 . A compound of formula I
and pharmaceutically acceptable salts and solvates thereof, characterized in that the compound is in particulate form, at least about 90% of said particles having a particle size of less than about 50 microns.
13 . The compound of claim 12 wherein at least about 90% of said particles have a size of less than 35 microns.
14 . The compound of claim 13 wherein said particles have a mean particle size of less than about 25 microns.
15 . The compound of claim 14 wherein said particles have a mean particles size of between about 5 and about 20 microns.
16 . A compound of claim 12 which is the non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride, having substantially the following X-ray diffraction pattern obtained with copper radiation:
d-line spacing
I/I o
(Angstroms)
(×100)
13.3864
71.31
9.3598
33.16
8.4625
2.08
7.3888
7.57
6.9907
5.80
6.6346
51.04
6.1717
29.57
5.9975
5.67
5.9135
9.87
5.6467
38.47
5.4773
10.54
5.2994
4.74
4.8680
4.03
4.7910
5.98
4.6614
57.50
4.5052
5.75
4.3701
9.03
4.2516
69.99
4.2059
57.64
4.1740
65.07
4.0819
12.44
3.9673
22.53
3.9318
100.00
3.8775
9.07
3.7096
33.38
3.6561
21.65
3.5576
3.36
3.5037
7.97
3.4522
18.02
3.4138
4.65
3.2738
10.23
3.1857
8.90
3.1333
6.24
3.0831
9.43
3.0025
12.13
2.9437
4.96
2.8642
7.70
2.7904
11.95
2.7246
3.05
2.6652
3.32
2.5882
7.30
17 . A pharmaceutical formulation comprising or formulated using the compound of claim 16 , and one or more pharmaceutically acceptable carriers, diluents, or excipients.
18 . A pharmaceutical composition comprising or formulated using a compound according to claim 12 , or a pharmaceutically acceptable salt or solvate thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
19 . A method of inhibiting osteoporosis comprising administering to a person in need thereof an effective amount of a compound of claim 12 , or a pharmaceutically acceptable salt or solvate thereof.
20 . A method of lowering serum lipid levels, comprising administering to a person in need thereof an effective amount of a compound of claim 12 , or a pharmaceutically acceptable salt or solvate thereof.
21 . A method for preventing breast cancer comprising administering to a woman in need thereof an effective amount of a compound of claim 12 , or a pharmaceutically acceptable salt or solvate thereof.
22 . An article of manufacture comprising packaging material containing a pharmaceutical formulation, said packaging material further containing labelling indicating said pharmaceutical formulation is useful for inhibiting a human pathology, said pharmaceutical formulation comprising or formulated using a compound of claim 12 .
23 . A compound of formula I
and pharmaceutically acceptable salts and solvates thereof, characterized in that the compound is in particulate form, said particles having a mean particle size of between about and about 20 microns, at least about 90% of said particles having a size of less than about 35 microns.
24 . A compound according to claim 23 wherein it is the hydrochloride salt thereof.
25 . A compound of claim 23 which is the non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b] thiophene hydrochloride, having substantially the following x-ray diffraction pattern obtained with copper radiation:
d-line spacing
I/I o
(Angstroms)
(×100)
13.3864
71.31
9.3598
33.16
8.4625
2.08
7.3888
7.57
6.9907
5.80
6.6346
51.04
6.1717
29.57
5.9975
5.67
5.9135
9.87
5.6467
38.47
5.4773
10.54
5.2994
4.74
4.8680
4.03
4.7910
5.98
4.6614
57.50
4.5052
5.75
4.3701
9.03
4.2516
69.99
4.2059
57.64
4.1740
65.07
4.0819
12.44
3.9673
22.53
3.9318
100.00
3.8775
9.07
3.7096
33.38
3.6561
21.65
3.5576
3.36
3.5037
7.97
3.4522
18.02
3.4138
4.65
3.2738
10.23
3.1857
8.90
3.1333
6.24
3.0831
9.43
3.0025
12.13
2.9437
4.96
2.8642
7.70
2.7904
11.95
2.7246
3.05
2.6652
3.32
2.5882
7.30
26 . A pharmaceutical formulation comprising or formulated using the compound of claim 25 and one or more pharmaceutically-acceptable carriers, diluents, or excipients.
27 . A pharmaceutical composition comprising or formulated using a compound according to claim 23 , or a pharmaceutically acceptable salt or solvate thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
28 . A method for inhibiting osteoporosis comprising administering to a person in need thereof an effective amount of a compound of claim 23 , or a pharmaceutically acceptable salt or solvate thereof.
29 . A method of lowering serum lipid levels, comprising administering an effective amount of a compound of claim 23 , or a pharmaceutically acceptable salt or solvate thereof, to a person in need thereof.
30 . A method for preventing breast cancer comprising administering to a woman in need thereof an effective amount of a compound of claim 23 , or a pharmaceutically acceptable salt or solvate thereof.
31 . An article of manufacture comprising packaging material containing a pharmaceutical formulation, said packaging material further containing labelling indicating said pharmaceutical formulation is useful for inhibiting a human pathology, said pharmaceutical formulation comprising or formulated using a compound of claim 23.Join the waitlist — get patent alerts
Track US2005239840A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.